Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 3.54
PTLA's Cash-to-Debt is ranked lower than
65% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. PTLA: 3.54 )
Ranked among companies with meaningful Cash-to-Debt only.
PTLA' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.46  Med: No Debt Max: No Debt
Current: 3.54
2.46
No Debt
Equity-to-Asset 0.62
PTLA's Equity-to-Asset is ranked lower than
59% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PTLA: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
PTLA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.82 Max: 0.91
Current: 0.62
0.36
0.91
Debt-to-Equity 0.38
PTLA's Debt-to-Equity is ranked lower than
54% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. PTLA: 0.38 )
Ranked among companies with meaningful Debt-to-Equity only.
PTLA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.27  Med: 0.35 Max: 0.99
Current: 0.38
0.27
0.99
Debt-to-EBITDA -0.37
PTLA's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. PTLA: -0.37 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PTLA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.42  Med: -0.32 Max: -0.22
Current: -0.37
-0.42
-0.22
Piotroski F-Score: 4
Altman Z-Score: 3.87
Beneish M-Score: -1.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1319.26
PTLA's Operating Margin % is ranked lower than
79% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. PTLA: -1319.26 )
Ranked among companies with meaningful Operating Margin % only.
PTLA' s Operating Margin % Range Over the Past 10 Years
Min: -1882.15  Med: -779.33 Max: 25.46
Current: -1319.26
-1882.15
25.46
Net Margin % -1365.43
PTLA's Net Margin % is ranked lower than
80% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. PTLA: -1365.43 )
Ranked among companies with meaningful Net Margin % only.
PTLA' s Net Margin % Range Over the Past 10 Years
Min: -1876.59  Med: -774.64 Max: 25.61
Current: -1365.43
-1876.59
25.61
ROE % -121.37
PTLA's ROE % is ranked lower than
79% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. PTLA: -121.37 )
Ranked among companies with meaningful ROE % only.
PTLA' s ROE % Range Over the Past 10 Years
Min: -121.37  Med: -42.58 Max: 9.6
Current: -121.37
-121.37
9.6
ROA % -70.01
PTLA's ROA % is ranked lower than
71% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. PTLA: -70.01 )
Ranked among companies with meaningful ROA % only.
PTLA' s ROA % Range Over the Past 10 Years
Min: -70.01  Med: -36.95 Max: 20.67
Current: -70.01
-70.01
20.67
ROC (Joel Greenblatt) % -5722.43
PTLA's ROC (Joel Greenblatt) % is ranked lower than
81% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. PTLA: -5722.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PTLA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5722.43  Med: -4328.31 Max: 1029.06
Current: -5722.43
-5722.43
1029.06
3-Year Revenue Growth Rate 19.20
PTLA's 3-Year Revenue Growth Rate is ranked higher than
72% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. PTLA: 19.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PTLA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -56.2 Max: 19.2
Current: 19.2
0
19.2
3-Year EBITDA Growth Rate -13.00
PTLA's 3-Year EBITDA Growth Rate is ranked lower than
70% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. PTLA: -13.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PTLA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -9.1
Current: -13
3-Year EPS without NRI Growth Rate -14.70
PTLA's 3-Year EPS without NRI Growth Rate is ranked lower than
73% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. PTLA: -14.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PTLA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -9.3
Current: -14.7
GuruFocus has detected 3 Warning Signs with Portola Pharmaceuticals Inc PTLA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PTLA's 30-Y Financials

Financials (Next Earnings Date: 2018-08-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

PTLA Guru Trades in Q2 2017

Paul Tudor Jones 16,419 sh (New)
Jim Simons 377,200 sh (New)
Ken Fisher 46,637 sh (unchged)
Joel Greenblatt 23,898 sh (-13.76%)
» More
Q3 2017

PTLA Guru Trades in Q3 2017

Leon Cooperman 50,000 sh (New)
Paul Tudor Jones 31,961 sh (+94.66%)
Jim Simons 528,500 sh (+40.11%)
Ken Fisher 61,893 sh (+32.71%)
Joel Greenblatt Sold Out
» More
Q4 2017

PTLA Guru Trades in Q4 2017

Vanguard Health Care Fund 168,887 sh (New)
Pioneer Investments 107,959 sh (New)
Ken Fisher 96,654 sh (+56.16%)
Leon Cooperman Sold Out
Jim Simons 352,800 sh (-33.25%)
Paul Tudor Jones 7,580 sh (-76.28%)
» More
Q1 2018

PTLA Guru Trades in Q1 2018

Leucadia National 15,000 sh (New)
Vanguard Health Care Fund 2,913,937 sh (+1625.38%)
Pioneer Investments 174,859 sh (+61.97%)
Jim Simons 366,400 sh (+3.85%)
Ken Fisher 96,654 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:PTLA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-03-31 Add 1625.38%0.2%$30.57 - $54.27 $ 40.01-9%2,913,937
Leucadia National 2018-03-31 New Buy0.03%$30.57 - $54.27 $ 40.01-9%15,000
Vanguard Health Care Fund 2017-12-31 New Buy0.02%$47.02 - $55.54 $ 40.01-21%168,887
Ken Fisher 2017-12-31 Add 56.16%$47.02 - $55.54 $ 40.01-21%96,654
Leon Cooperman 2017-12-31 Sold Out 0.1%$47.02 - $55.54 $ 40.01-21%0
Ken Fisher 2017-09-30 Add 32.71%$52.03 - $66.04 $ 40.01-32%61,893
Leon Cooperman 2017-09-30 New Buy0.1%$52.03 - $66.04 $ 40.01-32%50,000
Joel Greenblatt 2017-09-30 Sold Out 0.02%$52.03 - $66.04 $ 40.01-32%0
Joel Greenblatt 2017-06-30 Reduce -13.76%$35.06 - $56.91 $ 40.011%23,898
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XMCE:ALM, LSE:GNS, NAS:DNLI, ROCO:4147, NYSE:XON, SZSE:300294, NAS:CORT, SZSE:002287, XKRX:006280, SZSE:002653, NAS:SGMO, NAS:AKCA, NAS:ESPR, NAS:RXDX, NAS:MYOK, NAS:XLRN, NAS:EDIT, XKRX:095700, NAS:SPPI, NYSE:CBM » details
Traded in other countries:0PP.Germany,
Headquarter Location:USA
Portola Pharmaceuticals Inc is engaged in the healthcare sector. It develops & commercializes novel therapeutics to combat thrombosis, hematologic disorders & inflammation.

Portola Pharmaceuticals is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.

Top Ranked Articles about Portola Pharmaceuticals Inc

Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors
U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors
Factors of Influence in 2018, Key Indicators and Opportunity within Independent Bank Group, Eclipse Resources, Stellus Capital Investment, International Bancshares, Portola Pharmaceuticals, and Revance Therapeutics — New Research Emphasizes Economic Gro
Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban
Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018

Ratios

vs
industry
vs
history
PB Ratio 8.53
PTLA's PB Ratio is ranked lower than
66% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. PTLA: 8.53 )
Ranked among companies with meaningful PB Ratio only.
PTLA' s PB Ratio Range Over the Past 10 Years
Min: 3.07  Med: 5.13 Max: 34.25
Current: 8.53
3.07
34.25
PS Ratio 104.50
PTLA's PS Ratio is ranked lower than
83% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PTLA: 104.50 )
Ranked among companies with meaningful PS Ratio only.
PTLA' s PS Ratio Range Over the Past 10 Years
Min: 28  Med: 97.1 Max: 285.93
Current: 104.5
28
285.93
EV-to-EBIT -7.39
PTLA's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. PTLA: -7.39 )
Ranked among companies with meaningful EV-to-EBIT only.
PTLA' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.3  Med: -8 Max: -1.3
Current: -7.39
-14.3
-1.3
EV-to-EBITDA -7.45
PTLA's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. PTLA: -7.45 )
Ranked among companies with meaningful EV-to-EBITDA only.
PTLA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.5  Med: -8.1 Max: -1.3
Current: -7.45
-14.5
-1.3
EV-to-Revenue 97.10
PTLA's EV-to-Revenue is ranked lower than
78% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. PTLA: 97.10 )
Ranked among companies with meaningful EV-to-Revenue only.
PTLA' s EV-to-Revenue Range Over the Past 10 Years
Min: 10.3  Med: 83.45 Max: 261.8
Current: 97.1
10.3
261.8
Current Ratio 7.59
PTLA's Current Ratio is ranked higher than
63% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. PTLA: 7.59 )
Ranked among companies with meaningful Current Ratio only.
PTLA' s Current Ratio Range Over the Past 10 Years
Min: 4.94  Med: 7.6 Max: 10.67
Current: 7.59
4.94
10.67
Quick Ratio 7.53
PTLA's Quick Ratio is ranked higher than
65% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. PTLA: 7.53 )
Ranked among companies with meaningful Quick Ratio only.
PTLA' s Quick Ratio Range Over the Past 10 Years
Min: 4.94  Med: 7.6 Max: 10.67
Current: 7.53
4.94
10.67
Days Inventory 422.54
PTLA's Days Inventory is ranked lower than
71% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. PTLA: 422.54 )
Ranked among companies with meaningful Days Inventory only.
PTLA' s Days Inventory Range Over the Past 10 Years
Min: 422.54  Med: 483.3 Max: 483.3
Current: 422.54
422.54
483.3
Days Sales Outstanding 25.68
PTLA's Days Sales Outstanding is ranked higher than
53% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. PTLA: 25.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
PTLA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.16  Med: 7.59 Max: 60.71
Current: 25.68
2.16
60.71
Days Payable 10.00
PTLA's Days Payable is ranked lower than
86% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. PTLA: 10.00 )
Ranked among companies with meaningful Days Payable only.
PTLA' s Days Payable Range Over the Past 10 Years
Min: 10  Med: 8183.04 Max: 8183.04
Current: 10
10
8183.04

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.20
PTLA's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. PTLA: -10.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PTLA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29.3  Med: -10.2 Max: 0
Current: -10.2
-29.3
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.98
PTLA's Price-to-Net-Cash is ranked lower than
56% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. PTLA: 11.98 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PTLA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.52  Med: 6.83 Max: 43.21
Current: 11.98
3.52
43.21
Price-to-Net-Current-Asset-Value 10.64
PTLA's Price-to-Net-Current-Asset-Value is ranked lower than
60% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. PTLA: 10.64 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PTLA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.3  Med: 6.63 Max: 35.55
Current: 10.64
3.3
35.55
Price-to-Tangible-Book 8.77
PTLA's Price-to-Tangible-Book is ranked lower than
59% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. PTLA: 8.77 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PTLA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 5.26 Max: 31.45
Current: 8.77
3.14
31.45
Price-to-Median-PS-Value 1.08
PTLA's Price-to-Median-PS-Value is ranked lower than
53% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. PTLA: 1.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PTLA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 0.97 Max: 2.34
Current: 1.08
0.36
2.34
Earnings Yield (Greenblatt) % -13.51
PTLA's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. PTLA: -13.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PTLA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -76.3  Med: -12.4 Max: -7
Current: -13.51
-76.3
-7

More Statistics

Revenue (TTM) (Mil) $24.06
EPS (TTM) $ -5.34
Beta1.84
Volatility67.67%
52-Week Range $30.10 - 67.10
Shares Outstanding (Mil)65.83

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 58 308 622
EBIT (Mil $) -379 -145 131
EBITDA (Mil $) -377 -142 134
EPS ($) -5.85 -3.86 1.78
EPS without NRI ($) -5.85 -3.86 1.78
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}